|
Characteristics of the patients, according to the presence of steatosis. |
||||||
| Characteristic |
Steatosis Training Group |
Steatosis Validation Group 1 – HCV before treatment |
||||
|
|
||||||
| < 5%, n = 170 |
≥ 5%, n = 140 |
P value |
No, n = 126 |
Yes, n = 45 |
P value |
|
|
|
||||||
| Demographics |
||||||
| Age at biopsy, years |
46.7 (12.4) |
51.8 (12.1) |
0.0004 |
43.7 (7.3) |
45.2 (7.0) |
0.28 |
| Male gender |
110 (55%) |
91 (45%) |
0.96 |
81 (64%) |
30 (67%) |
0.77 |
| BMI |
24 (4) |
27 (6) |
< 0.0001 |
27 (5) |
31 (4) |
< 0.0001 |
| Biochemical markers |
||||||
| α2-macroglobulin, g/L |
2.47 (1.00) |
2.30 (1.04) |
0.07 |
3.10 (1.23) |
3.20 (1.24) |
0.50 |
| ALT, IU/L |
104 (119) |
115 (108) |
0.02 |
46 (45) |
61 (48) |
0.003 |
| AST, IU/L |
83 (204) |
83 (78) |
0.01 |
80 (61) |
88 (43) |
0.01 |
| Apolipoprotein A1, g/L |
1.46 (0.34) |
1.42 (0.33) |
0.30 |
1.27 (0.26) |
1.20 (0.24) |
0.18 |
| Haptoglobin, g/L |
0.93 (0.60) |
0.96 (0.52) |
0.19 |
0.77 (0.45) |
0.78 (0.44) |
0.84 |
| GGT, IU/L |
83 (132) |
147 (226) |
< 0.0001 |
72 (85) |
118 (116) |
0.0007 |
| Total bilirubin, μmol/L |
14.8 (31.4) |
14.7 (17.8) |
0.47 |
11.0 (5.0) |
11.3 (4.1) |
0.38 |
| Glucose mmol/L |
5.1 (3.7) |
5.9 (2.2) |
< 0.0001 |
5.2 (0.9) |
6.0 (1.8) |
0.0007 |
| Triglycerides, mmol/L |
1.24 (0.95) |
1.88 (1.78) |
< 0.0001 |
1.26 (0.72) |
1.72 (1.0) |
0.0008 |
| Total cholesterol, mmol/L |
4.8 (1.2) |
5.1 (1.4) |
0.10 |
4.5 (1.0) |
4.4 (1.0) |
0.10 |
| FibroTest |
0.40 (0.29) |
0.45 (0.28) |
0.47 |
0.45 (0.26) |
0.53 (0.24) |
0.07 |
| SteatoTest |
0.38 (0.21) |
0.62 (0.22) |
< 0.0001 |
0.47 (0.21) |
0.70 (0.16) |
< 0.0001 |
|
|
||||||
| Characteristic |
Steatosis Validation Group 2 – HCV sustained responders |
Steatosis Validation Group 3 – Alcoholic liver disease |
||||
|
|
||||||
| No n = 179 |
Yes n = 22 |
P value |
< 5%, n = 4 |
≥ 5%, n = 58 |
P value |
|
|
|
||||||
| Demographics |
||||||
| Age at biopsy, years |
43.7 (8.1) |
43.1 (7.0) |
0.7 |
38.0 (12.8) |
47 (9.4) |
0.16 |
| Male gender |
110 (62%) |
12 (55%) |
0.53 |
2 (50%) |
45 (78%) |
0.21 |
| BMI |
26 (4) |
31 (6) |
<0.0001 |
22.9 (2.9) |
24.3 (4.2) |
0.49 |
| Biochemical markers |
||||||
| α2-macroglobulin, g/L |
2.08 (0.79) |
1.73 (0.66) |
0.06 |
2.12 (0.53) |
1.81 (0.55) |
0.26 |
| ALT, IU/L |
18 (9) |
26 (9) |
<0.0001 |
35 (24) |
74 (90) |
0.10 |
| AST, IU/L |
23 (9) |
25 (7) |
0.06 |
74 (43) |
58 (90) |
1.00 |
| Apolipoprotein A1, g/L |
1.16 (0.28) |
1.07 (0.25) |
0.2 |
1.67 (0.43) |
1.48 (0.49) |
0.49 |
| Haptoglobin, g/L |
0.85 (0.41) |
0.94 (0.56) |
0.85 |
1.55 (0.92) |
1.38 (0.62) |
0.85 |
| GGT, IU/L |
20 (18) |
28 (14) |
0.0002 |
327 (184) |
323 (323) |
0.41 |
| Total bilirubin, μmol/L |
8.9 (4.6) |
8.1 (4.3) |
0.3 |
28.5 (23.4) |
21.1 (19.5) |
0.28 |
| Glucose, mmol/L |
5.3 (1.0) |
5.5 (0.8) |
0.16 |
6.5 (2.2) |
5.7 (1.6) |
0.46 |
| Triglycerides, mmol/L |
1.49 (0.98) |
2.05 (1.22) |
0.003 |
1.05 (0.51) |
1.96 (3.15) |
0.28 |
| Total cholesterol, mmol/L |
5.0 (1.0) |
5.1 (0.9) |
0.51 |
6.0 (1.38) |
5.4 (2.0) |
0.68 |
| FibroTest |
0.29 (0.20) |
0.26 (0.19) |
0.46 |
0.43 (0.32) |
0.43 (0.28) |
0.79 |
| SteatoTest |
0.32 (0.20) |
0.62 (0.17) |
<0.0001 |
0.44 (0.03) |
0.59 (0.26) |
0.21 |
|
Data are mean (SD) or proportion. | ||||||
Poynard et al. Comparative Hepatology 2005 4:10 doi:10.1186/1476-5926-4-10 |
||||||